← Leaderboards
Eric Bruening
Tomegavax, Inc.
$7,161,734
Attributed
$7,274,069
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2014–19$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,274,069 · 5
By mechanism
R44$6,824,439 · 3
R43$449,630 · 2
Top collaborators
- Emily Elizabeth Marshall1 shared
Most similar at Tomegavax, Inc.
Same institution · by research overlap
- Emily Elizabeth Marshall$412,171
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityImmuneInfectionVaccinesNonhuman PrimateTherapeutic VaccineImmune ResponseImmunotherapyVectorT Memory CellT-LymphocyteSafetyEpitopesT Cell ResponseCytomegalovirusAntigensBaseVirusMediatingClinical TrialsIn VitroDosePeripheralResponse
Grant awards (10)
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$1,000,000
R44 · FY2019 · AI · contact PI
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$685,089
R44 · FY2018 · AI · contact PI
A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses$928,329
R44 · FY2017 · CA · contact PI
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B$297,434
R44 · FY2017 · AI · contact PI
A human cytomegalovirus-based immunotherapy for HIV-1$986,188
R44 · FY2016 · AI · contact PI
A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses$948,184
R44 · FY2016 · CA · contact PI
A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine$224,959
R43 · FY2016 · AI · contact PI
A human cytomegalovirus-based immunotherapy for HIV-1$986,519
R44 · FY2015 · AI · contact PI
A human cytomegalovirus-based immunotherapy for HIV-1$992,696
R44 · FY2014 · AI · contact PI
An effector memory T cell-based therapeutic cervical cancer vaccine$224,671
R43 · FY2014 · CA · contact PI